Evaluate molecular testing and treatment patterns for EGFR mutation in two different cohorts of stage IV NSCLC, at diagnosis (treatment naïve) and at the moment of progression to EGFR-TKIs. This study is non-indication seeking (NIS), descriptive in nature and does not attempt to test any specific a priori hypotheses.
Description: Test used to determine EGFRm, registered in clinical chartsMeasure: Evaluation of the EGFR mutation Time: Clinical charts from January 2013-december 2017
There is one SNP
Study Measures - Patient demographic and clinical characteristics - Molecular testing rates at Stage IV and at progression to EGFR TKI - Molecular testing EGFR mutation results (common/uncommon mutations at advanced diagnosis, and T790M at progression) - Treatment patterns at frontline and progression to EGFR TKIs - Biopsy-related complications - Percentage of patinets presenting with CNS metastasis at diagnosis of stage IV and at progression to EGFR TKIsCNS Sample: All patients diagnosed with Stage IV NSCLC at diagnosis and at progression to an EGFR-TKI; from January 1st , 2017 to December 31st, 2017 in selected centers of Uruguay, Argentina, Chile, Colombia Statistical Analysis No formal hypothesis testing is specified. --- T790M ---